Andrew James King

Andrew James King (senior executive) discloses dealings in 2 companies, chiefly Chinook Therapeutics, Inc. and Jade Biosciences, Inc. We count 29 filings; the first trade dates from 6 October 2021 and the latest from 12 February 2026.

The open-market record consists of 13 sales worth €991k, with no purchase. The rest of the record consists of 2 share grants and 13 option exercises.

The latest filing, published on 13 February 2026, reports a share grant in Jade Biosciences, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.